Seagull Pharmaceuticals Pvt Ltd - Due diligence report

A 360° intelligence report on Seagull Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals…

1984-11-21 Naraina Vihar, Delhi Active Unlisted Active Compliant
Share
SP Seagull Pharmaceuticals Pvt Ltd
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Seagull Pharma — 360° Intelligence Report

Generated from MCA filings & public records
89/100
Trust Score
Low Risk

Seagull Pharma is assessed as Low Risk with a Trust Score of 89/100. Seagull Pharma is an active private limited indian non-government company incorporated in 1984, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Seagull Pharmaceuticals Pvt Ltd snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
89/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
74/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 2 satisfied (2.80 cr).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of Bikaner & Jaipur2 48.0 cr
Compliance Score: 74/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 2 court forum(s).
  • 4 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SUBHASH MALHOTRA 01234567 Director 01/04/2018 6 yrs Approved
RISHABH SINGHAL 01234567 Director 01/04/2018 6 yrs Approved
SALIL MALHOTRA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 6 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 80 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Asset base grew 24% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 41+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment90/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
11 May 2023
Director ceased
SUBHASH MALHOTRA
31 Mar 2022
Share transfer (FY 2022)
200000.00000000 shares to Salil Malhotra
15 Nov 2021
Charge satisfied
State Bank Of Bikaner & Jaipur
30 Jun 2020
Director ceased
AJAY BANSAL
31 Mar 2018
Share transfer (FY 2018)
50000.00000000 shares to SUBHASH MALHOTRA
Share transfer (FY 2018)
60.00000000 shares to SUBHASH MALHOTRA
Share transfer (FY 2018)
22500.00000000 shares to SALIL MALHOTRA
Share transfer (FY 2018)
50000.00000000 shares to RISHABH MALHOTRA
30 Mar 2012
Securities allotted
50050.00 Equity Shares - 5.01 Lakh raised
15 Nov 2010
Securities allotted
72000.00 Equity Shares - 7.20 Lakh raised
02 Feb 2008
Charge satisfied
State Bank Of Bikaner & Jaipur
14 Jan 2008
Charge created
State Bank Of Bikaner & Jaipur - 2.00 cr
27 Jul 2007
Director appointed
SALIL MALHOTRA (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
4 active GST registration(s) indicate ongoing business operations.
All 2 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Sameeksha Pharmaceuticals Private Limited U24302PN2016PTC164262 Haveli, Maharashtra, India
Sarv Bio Labs Private Limited U24234HP2005PTC027851 Himachal Pradesh, Himachal Pradesh, India
Colorant Limited U24110GJ1999PLC036748 Ahmedabad, Gujarat, India
Epsilonpharma U24230GJ1998PTC084755 Ahmedabad, Gujarat, India
Chemcrux Enterprises L01110GJ1996PLC029329 Vadodara, Gujarat, India
Novomedi U33110MH2013PTC245027 Mumbai, Maharashtra, India
Apra Innovative Private Limited U24299MH2021PTC363909 Mumbai, Maharashtra, India
Sirmour Remedies Private Limited U15311HP1989PTC009770 Paonta Sahib, Himachal Pradesh, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Seagull Pharma before audits and certifications: compliance score 74/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Seagull Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Seagull Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 89/100, distress signals and MSME payment-delay disclosures - know whether Seagull Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Seagull Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Seagull Pharma an active company?

Seagull Pharma has MCA status “Active” with a compliance score of 74/100 (Moderate).

Is Seagull Pharma financially healthy?

Seagull Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Seagull Pharma?

Its overall Trust Score is 89/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Seagull Pharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Seagull Pharma have loans or charges against its assets?

No open charges - all 2 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Seagull Pharma up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 74/100 (Moderate).

Is it risky to lend to Seagull Pharma?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.